BioXcel Therapeutics (BTAI) Misses Q1 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioXcel Therapeutics (BTAI) Reports Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501
May 14, 2020 7:09 AM EDTBioXcel Therapeutics, Inc. (NASDAQ: BTAI) today announced full enrollment of its pivotal Phase 3 SERENITY trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder. The Company expects to report topline data from both trials in July of 2020.
Completing patient enrollment in our two Phase 3 studies marks a significant milestone for BTI, and lays the foundation for future growth as we look to pursue clinical trials for several additional indications for BXCL501, commented Vimal Mehta, Ph.D., Chief Executive Officer of BTAI. The BTI team has remained focused, with... More
